167 related articles for article (PubMed ID: 25365354)
1. A review of emerging trends in the treatment of tuberculosis.
Kaur M; Garg T; Narang RK
Artif Cells Nanomed Biotechnol; 2016; 44(2):478-84. PubMed ID: 25365354
[TBL] [Abstract][Full Text] [Related]
2. Colloidal carriers: a rising tool for therapy of tuberculosis.
Gupta S; Kumar P; Gupta MK; Vyas S
Crit Rev Ther Drug Carrier Syst; 2012; 29(4):299-53. PubMed ID: 22746187
[TBL] [Abstract][Full Text] [Related]
3. Development of nanoparticles for antimicrobial drug delivery.
Zhang L; Pornpattananangku D; Hu CM; Huang CM
Curr Med Chem; 2010; 17(6):585-94. PubMed ID: 20015030
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery.
Sosnik A; Carcaboso AM; Glisoni RJ; Moretton MA; Chiappetta DA
Adv Drug Deliv Rev; 2010 Mar; 62(4-5):547-59. PubMed ID: 19914315
[TBL] [Abstract][Full Text] [Related]
6. Advanced drug delivery and therapeutic strategies for tuberculosis treatment.
Nair A; Greeny A; Nandan A; Sah RK; Jose A; Dyawanapelly S; Junnuthula V; K V A; Sadanandan P
J Nanobiotechnology; 2023 Nov; 21(1):414. PubMed ID: 37946240
[TBL] [Abstract][Full Text] [Related]
7. Nanostructured Therapeutic Carriers for Tuberculosis Treatment: Approaches & Challenges.
Ullah Z; Athar MT; Samad A
Recent Pat Antiinfect Drug Discov; 2017; 12(2):128-137. PubMed ID: 28990537
[TBL] [Abstract][Full Text] [Related]
8. Nanostructured drug delivery for better management of tuberculosis.
Kaur IP; Singh H
J Control Release; 2014 Jun; 184():36-50. PubMed ID: 24732260
[TBL] [Abstract][Full Text] [Related]
9. The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy.
Mortensen NP; Durham P; Hickey AJ
J Microencapsul; 2014; 31(8):785-95. PubMed ID: 25090595
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology based drug delivery system(s) for the management of tuberculosis.
Pandey R; Khuller GK
Indian J Exp Biol; 2006 May; 44(5):357-66. PubMed ID: 16708887
[TBL] [Abstract][Full Text] [Related]
11. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
12. Liposomes as drug delivery systems for the treatment of TB.
Pinheiro M; Lúcio M; Lima JL; Reis S
Nanomedicine (Lond); 2011 Oct; 6(8):1413-28. PubMed ID: 22026379
[TBL] [Abstract][Full Text] [Related]
13. [Nanoparticles as drug delivery system for antituberculous drugs].
Sanzhakov MA; Ipatova OM; Torkhovskaia TI; Prozorovskiĭ VN; Tikhonova EG; Druzhilovskaia OS; Medvedeva NV
Vestn Ross Akad Med Nauk; 2013; (8):37-44. PubMed ID: 24340644
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis.
Chimote G; Banerjee R
J Biomed Mater Res A; 2009 May; 89(2):281-92. PubMed ID: 18431766
[TBL] [Abstract][Full Text] [Related]
15. Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis.
Manca ML; Cassano R; Valenti D; Trombino S; Ferrarelli T; Picci N; Fadda AM; Manconi M
J Pharm Pharmacol; 2013 Sep; 65(9):1302-11. PubMed ID: 23927468
[TBL] [Abstract][Full Text] [Related]
16. Respirable rifampicin-based microspheres containing isoniazid for tuberculosis treatment.
Cassano R; Trombino S; Ferrarelli T; Mauro MV; Giraldi C; Manconi M; Fadda AM; Picci N
J Biomed Mater Res A; 2012 Feb; 100(2):536-42. PubMed ID: 22162280
[TBL] [Abstract][Full Text] [Related]
17. Nano-carriers for the Treatment of Tuberculosis.
Gilani SJ; Ameeduzzafar ; Jafar M; Shakil K; Imam SS
Recent Pat Antiinfect Drug Discov; 2017; 12(2):95-106. PubMed ID: 28595544
[TBL] [Abstract][Full Text] [Related]
18. The formulation of nanomedicines for treating tuberculosis.
Costa A; Pinheiro M; Magalhães J; Ribeiro R; Seabra V; Reis S; Sarmento B
Adv Drug Deliv Rev; 2016 Jul; 102():102-15. PubMed ID: 27108703
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs.
Kaur R; Garg T; Malik B; Gupta UD; Gupta P; Rath G; Goyal AK
Drug Deliv; 2016; 23(3):882-7. PubMed ID: 24870203
[TBL] [Abstract][Full Text] [Related]
20. Fighting tuberculosis: old drugs, new formulations.
Blasi P; Schoubben A; Giovagnoli S; Rossi C; Ricci M
Expert Opin Drug Deliv; 2009 Sep; 6(9):977-93. PubMed ID: 19678791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
